Trekka Therapeutics, Inc. is a biomaterial platform company commercializing two proprietary drug delivery platforms — CAPRO™ (injectable depot) and MORE™ (oral wafer) — for pharma and consumer health partners. Trekka partners with pharma and consumer health companies to solve their hardest formulation challenges — solubility, stability, loading, bioavailability, and controlled release — across small molecule drugs, biologics and drug combinations, using two proprietary biomaterial platforms that go where no legacy excipient can go.
Poor solubility, biologic instability, uncontrolled release, and format limitations keep promising molecules from reaching their potential. That is the market CAPRO™ and MORE™ were built to address.
CAPRO™ handles the performance problem. MORE™ handles the delivery and experience problem. Used independently or together, they address the full formulation lifecycle.
A patented biodegradable polymer excipient platform. Functional blocks and cleavable linkers pre-program release kinetics at the molecular level — for injectable, oral, and topical applications. Room temperature, solvent-free, no acidic byproducts. Works for small molecules AND biologics.
A patent-pending multi-layer oral wafer platform. Dissolves without water, delivers transumsocally, and can be enhanced with CAPRO™ for poorly soluble APIs. Layer architecture is tuned per application — fast, extended, or biphasic kinetics engineered to the specific need before manufacture.
CAPRO™ and MORE™ address formulation challenges across small molecule drugs, biologics, vaccines, and drug combinations — in injectable, oral, and topical delivery formats.
Trekka's dual-platform model generates revenue on two timelines simultaneously — with the OTC path funding the Rx pipeline, not competing with it.
Two proprietary platforms. GMP-compatible processes. 505(b)(2) regulatory strategy from day one. And a commercial model that generates OTC revenue while the Rx pipeline advances.
Trekka Therapeutics, Inc. is a Saint Paul, MN-based biomaterial platform company founded in 2018. It commercializes two proprietary polymer drug delivery platforms — CAPRO™ (a patented injectable depot excipient) and MORE™ (a patent-pending oral wafer) — through partnerships with pharmaceutical and consumer health companies facing difficult formulation challenges.
CAPRO™ is Trekka's patented biodegradable polymer excipient. It uses cleavable linker architecture to pre-program controlled drug release at the molecular level — eliminating day-one burst release, acidic degradation byproducts, and organic solvent requirements that limit legacy platforms like PLGA. CAPRO™ is biologic-compatible and supports SubQ, IM, intra-articular, and biodegradable implant depot formats for small molecules, biologics, and combination formulations.
Trekka's platforms address eight core formulation challenges: poor API solubility (BCS II/IV), biologic instability (protein degradation during formulation or in vivo), short drug half-life requiring frequent dosing, burst release causing toxic concentration peaks, high drug loading limitations, unpredictable batch-to-batch release profiles, organic solvent residual risks, and wrong delivery format for the indication. CAPRO™ addresses injectable depot challenges; MORE™ addresses oral and transmucosal delivery challenges.
Trekka offers four engagement models: (1) Feasibility studies — targeted formulation experiments on a partner's specific API, typically 4–12 weeks; (2) Custom development programs — full formulation development through pre-clinical; (3) Co-development — shared development and commercial rights; (4) Technology licensing — license CAPRO™ or MORE™ platform IP and run your own program. All inquiries are confidential. Contact info@trekkatherapeutics.com.
CAPRO™-based programs support both the full NDA pathway for new molecular entities and the 505(b)(2) pathway for reformulations of existing APIs — leveraging available safety data to significantly reduce development cost and timelines. Trekka has received Pre-IND FDA feedback confirming the regulatory approach. CAPRO™ is currently advancing through pre-clinical development.